Davide Massa

MD, Resident in Medical Oncology

[Carmine De Angelis @CarmineDeA1]

Does Trop-2 expression matter? Yes 😌

📖Our @JNCI_Now meta-analysis of randomized trials shows that Trop-2 ADCs provide the greatest PFS benefit in Trop-2–high MBC
⏰ It is time to develop standardized and clinically meaningful Trop-2 assays 💪

🔗 https://t.co/4QBrorTXvV

[Gaia Griguolo @GaiaGriguolo]

Exploratory analysis of A-BRAVE trial: infusion timing of avelumab not associated with outcome

Timing effect appears to depend on baseline tumor immune milieu: benefit from AM infusion in high baseline TILs and from PM infusion in low baseline TILs

@OncoAlert #asco26 @vitti10

[Lorenzo Galluzzi @deadoc80]

Happy to share our latest @NatRevImmunol review on the #immunology of breast #cancer in #patients. Kudos to @bk_esme and @txi_ber for the monumental effort. Not possible w/o critical input from @LoiSher & Roberto Salgado! @FoxChaseCancer @PeterMacCC See https://t.co/MHaF4ankp9

[Davide Massa @massa12d]

Should pts with ER-low (1-9%) BC receive ET? 💊

Our meta-analysis of published studies (n=9711) shows:
> Higher risk for ER-low vs ER+ (2x)

With ET:
⬇️Relapse: HR 0.74
⬇️Death: HR 0.80

#SABCS25 @vitti10 @matteolambe @GaiaGriguolo

[Maria Vittoria Dieci @vitti10]

TILs matter in HER2+ BC!

In ShortHER trial, mapping their spatial organization with AI assessing:
🔹Immune-tumor interaction
🔹Aggregates/TLS (Hotspots)
further refines prognosis beyond manual evaluation

PS2-08-11 at #Sabcs25 @UniPadova @iov_irccs @TILsWorkGroup

[Michele Bottosso @M_Bottosso]

Check out PS3-01-10 today at #SABCS25 on metastatic patterns in BRCA1/2 carriers:

🔹HR+: higher and earlier CNS involvement
🔹TNBC: fewer liver metastases, similar high CNS involvement

📍BRCA1/2 status may help tailor radiological surveillance

@vitti10 @GaiaGriguolo @massa12d

[Paolo Tarantino @PTarantinoMD]

Wow.

All the benefit of checkpoint inhibition in A-BRAVE (high-risk TNBC) was seen in patients with TILs ≥ 30%. No benefit with low TILs.

Unbelievable that we didn’t get to see the TILs data from KN522 yet. Hope we’ll see them soon.

Congrats @vitti10! #ESMO25 #ESMOAmbassadors

[Gaia Griguolo @GaiaGriguolo]

Out in @Annals_Oncology
A-BRAVE trial (adj avelumab in high-risk eTNBC):

DFS HR 0.81 ➡️ Not significant❌
OS (HR 0.66) & DDFS (HR 0.70) benefit ✅

→ PD-L1 prognostic, not predictive
https://t.co/vKyCX1ZEja

@OncoAlert @UniPadova @vitti10

[Federica Miglietta @FedeMiglietta]

#ASCO25 Excited to share the data from a wide Italian effort ⬇️
Among pts with stable ER>=10%/HER2- from primary to recurrent BC:
📍those with ER 10-30% have poor OS
📍those with consistently high ER % do well, but those with ER shifting from 10-30% to 50-100% do even better

[ESMO - Eur. Oncology @myESMO]

#ESMOBreast25: Low baseline tumour infiltrating lymphocytes #TILs and nodal involvement may predict #BreastCancer patients with poor prognosis despite pathological complete response to neoadjuvant chemotherapy.

#ESMODailyReporter has more

🔗 https://t.co/B6N4TNEGh6

[Matteo Lambertini, MD PhD @matteolambe]

Proffered paper session at #ESMOBreast25 with #DavideMassa from @vitti10 group showing important data on how to better stratify prognosis of patients with triple-negative #BreastCancer based on #TILs nodal status and pCR @myESMO #ESMOAmbassadors @OncoAlert #bcsm

[Simone Nardin @nardin_simone]

Baseline TILs are an independent prognostic tool for TNBC patients who achieved a pCR after neoadjuvant treatment. A well-deserved oral presentation by @massa12d! Congratulations 🎉🙏🏼 #ESMOBreast25 @OncoAlert

[Davide Massa @massa12d]

@vitti10

[JAMA Oncology @JAMAOnc]

Most viewed in the last 7 days from @JAMAOnc:

Tumor-infiltrating lymphocytes can serve as a biomarker to identify patients with ERBB2-positive early breast cancer who may safely undergo de-escalated adjuvant therapy without compromising long-term SO.

https://t.co/zkL7nixz8d

[Davide Massa @massa12d]

@vitti10

[JAMA Oncology @JAMAOnc]

Higher tumor-infiltrating lymphocytes (TILs) were strongly associated with improved overall survival in patients with ERBB2-positive early breast cancer. https://t.co/qDSZwzwT0U

[Simone Nardin @nardin_simone]

Honored and proud to present our data on suboptimal ovarian suppression as adjuvant treatment for HR+ EBC, receiving #SABCS24 Clinical Scholar Award!
A heartfelt thanks to my daily guide of the last 4 years, @Poggio_Fra , and my mentors @matteolambe @delmastro_lucia 🙏🏼@OncoAlert

[Simone Nardin @nardin_simone]

Really interesting data presented by my friend @massa12d on the first relapse site in TN EBC.
Despite achieving a pCR after NACT, the central nervous system is the predominant site of first recurrence. Must implement treatments to prevent brain met. Congrats🙏🏼 @OncoAlert #SABCS24

[Federica Miglietta @FedeMiglietta]

Important data presented today by @vitti10 at #ESMO24: first evidence of TILs impacting on OS in HER2+ #BC. Exciting results from the 9 yrs update of the Shorther trial, with intriguing considerations regarding selection for de-escalation. @UniPadova

[Yakup Ergün @dr_yakupergun]

Another study shows that ER-negative (<1%) and ER-low (1%-9%) tumors exhibit similar biological and molecular characteristics

💥Accumulating evidence suggests that ER-low tumors should be considered as ER-negative (if intrinsic subtype analysis cannot be performed)

@OncoAlert @JNCI_Now
https://t.co/NxUby9WpNT

[Federica Miglietta @FedeMiglietta]

Super proud that our work on a prognostic model for OS based on RCB + RD-TILs after NAT in HER2+ BC is finally out on @CCR_AACR!!
⬆️ TILs on RD —&gt; worse OS
⬆️ RCB-TIL scores —&gt; worse OS

@vitti10 @GaiaGriguolo @M_Bottosso

https://t.co/HJOQrmHg3n

[Andrea Franza, MD @andrea_franza]

Amazing experience this year at #ASCO2023!
So happy to have shared these days with other oncology fellows from different italian Universities

See you at #COMU2023!